Virios Therapeutics, Inc. (VIRI)
|52 Week Range||0.219-9.111|
|1y Target Est||-|
|DCF Unlevered||VIRI DCF ->|
|DCF Levered||VIRI LDCF ->|
|Debt / Equity||14.24%||Neutral|
Upgrades & Downgrades
Latest VIRI news
Best Penny Stocks To Buy Now? 10 To Watch Under $5
24 March 2023
Penny stocks to watch this week under $5 The post Best Penny Stocks To Buy Now? 10 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March ...
7 March 2023
ATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chr...
Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now
5 January 2023
Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
29 November 2022
ATLANTA--( BUSINESS WIRE )--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chroni...
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript
14 November 2022
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Fina...
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on M...
3 November 2022
ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat de...
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
24 October 2022
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.
These Were The Five Best And Worst Performing Healthcare Stocks In September 2022
17 October 2022
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.
Why Is Virios Therapeutics (VIRI) Stock Down 71% Today?
19 September 2022
Source: Shutterstock / PopTika Virios Therapeutics (NASDAQ: VIRI ) stock is falling hard on Monday after the company revealed results from its Phase 2b Study of IMC-1 in Fibromyalgia. IMC-1 is a treat...
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q2 2022 Results - Earnings Call Transcript
13 August 2022
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET CompanyParticipants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance...
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >